4.41

2.00% -0.09

Design Therapeutics Inc (DSGN)

Overview News Price History Option Chain Financials Discussions Forecast

Design Therapeutics Inc stock is currently priced at $4.41, with a 24-hour trading volume of 119.98K. It has seen a -2.00% decreased in the last 24 hours and a +11.93% rose in the past month. The chart indicates a potential bearish trend, as the stock is below the $4.49 pivot point. If it approaches the $4.34 support level, significant changes may occur.

Previous Close:

$4.50

Open:

$4.49

24h Volume:

119.98K

Market Cap:

$249.14M

Revenue:

Net Income/Loss:

$-66.86M

P/E Ratio:

-3.291

EPS:

-1.34

Net Cash Flow:

$-58.82M

1W Performance:

-3.50%

1M Performance:

+11.93%

6M Performance:

+98.65%

1Y Performance:

-35.53%

1D Range:

$4.37

$4.545

52W Range:

$1.94

$8.31

Design Therapeutics Inc Stock (DSGN) Company Profile

Name

Design Therapeutics Inc

Sector

Healthcare (1209)

Industry

Biotechnology (699)

Phone

858 293 4900

Address

6005 Hidden Valley Road, Suite 110, Carlsbad

Employee

Twitter

Next Earnings Date

2024-06-13

Latest SEC Filings

DSGN's Discussions on Twitter

Design Therapeutics Inc Stock (DSGN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
May-04-23	Upgrade	Goldman	Sell → Neutral
Jun-10-22	Initiated	Wedbush	Outperform
May-02-22	Initiated	RBC Capital Mkts	Outperform
Jan-19-22	Initiated	Goldman	Sell
Apr-20-21	Initiated	Goldman	Neutral
Apr-20-21	Initiated	Piper Sandler	Overweight
Apr-20-21	Initiated	SVB Leerink	Outperform

View All

Design Therapeutics Inc Stock (DSGN) Latest News

Design Therapeutics (DSGN) Price Target Increased by 18.30% to 27.03 - MSN

MSN

Design Therapeutics, Inc. Forecasted to Earn Q2 2024 Earnings of ($0.22) Per Share (NASDAQ:DSGN) - MarketBeat

MarketBeat

Design Therapeutics, Inc. (NASDAQ:DSGN) Given Consensus Rating of "Hold" by Brokerages - MarketBeat

MarketBeat

Dyno Therapeutics to Accelerate Design of High-Performance Biological Sequences Using NVIDIA AI - Yahoo Finance

Yahoo Finance

Dyno Therapeutics to Accelerate Design of High-Performance Biological Sequences Using NVIDIA AI - 01Net

01Net

Design Therapeutics Announces First Quarter 2024 Financial Results and Highlights Upcoming Program Milestones - Marketscreener.com

Marketscreener.com

Design Therapeutics Inc Stock (DSGN) Financials Data

Design Therapeutics Inc (DSGN) Net Income 2024

DSGN net income (TTM) was -$66.86 million for the quarter ending December 31, 2023, a -5.61% decrease year-over-year.

Design Therapeutics Inc (DSGN) Cash Flow 2024

DSGN recorded a free cash flow (TTM) of -$58.82 million for the quarter ending December 31, 2023, a -12.60% decrease year-over-year.

Design Therapeutics Inc (DSGN) Earnings per Share 2024

DSGN earnings per share (TTM) was -$1.20 for the quarter ending December 31, 2023, a -5.26% decline year-over-year.

Design Therapeutics Inc Stock (DSGN) Insider Trading

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total
Berger Heather A.	Director	Mar 25 '24	Buy	3.74	1,300	4,866	1,300
Schmid John P.	Director	Mar 22 '24	Buy	3.62	9,156	33,133	9,156
LAPPE RODNEY W	Director	Sep 29 '23	Buy	2.35	21,000	49,287	133,024
William Arsani	Director	Aug 29 '23	Buy	2.44	1,960,000	4,782,400	3,000,000
Prasad Deepa	Director	Aug 29 '23	Buy	2.31	12,000	27,670	23,806
William Arsani	Director	Aug 28 '23	Buy	2.15	275,000	591,250	1,040,000

Design Therapeutics, Inc. develops therapies for the treatment of degenerative disorders caused by nucleotide repeat expansions. The company engages in the development of a program for the treatment of Friedreich's ataxia and degenerative diseases such as Fragile X syndrome and myotonic dystrophy. The company was incorporated in 2017 and is based in Carlsbad, California.